Skip to main content
David Callanan, MD, Ophthalmology, Arlington, TX, Texas Health Arlington Memorial Hospital

DavidCallananMD

Ophthalmology Arlington, TX

Retinal Disease

Physician

Dr. Callanan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Callanan's full profile

Already have an account?

Education & Training

  • University of Miami/Jackson Health System/Bascom Palmer Eye Institute
    University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 1990 - 1992
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Ophthalmology, 1987 - 1990
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1983 - 1985
  • University of Iowa Roy J. and Lucille A. Carver College of Medicine
    University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1983
  • Luther College
    Luther CollegeB.A., 1975

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1984 - 2024
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
  • Senior Honor Award American Society of Retinal Specialists, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema  
    Callanan DG, Loewenstein A, Patel SS, Massin P, Corcostegui B, Li XY, Jiao J, Hashad Y, Whitcup SM, Graefes Arch Clin Exp Ophthalmol, 1/1/2017
  • Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel  
    Regillo CD, Callanan DG, Fine HF, Do DV, Holekamp NM, Kuppermann BD, Singer MA, Singh RP, Ophthalmic Surg Lasers Imaging Retina, 1/1/2017
  • Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study  
    Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, Do D, Ophthalmology, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • "Combination Therapy for Exudative Age Related Macular Degeneration"
    Callanan DG, XXVIth Meeting of the Club Jules Gonin, St. Moritz, Switzerland, 1/12/2008
  • Fluocinolone Acetonide Intravitreal Implant for the Treatment of Uveitis Affecting the Posterior Segment: 34 Week Results of a Randomized, Masked, Multi-center Clinica...
    Fluocinolone Acetonide Uveitis Study Group, American Uveitis Society, Vail, CO, 1/19/2004

Lectures

  • "The OZAB Study: A 6 Month, Prospective, Randomized Study of the Effects of Dexamethasone Intravitreal Implant with Bevacizumab Compared to Bevacizumab Alone for Centr... 
    Jersey, The Channel Islands - 1/13/2018
  • "Implantation of Drug Delivery Devices" 
    Guangzhou, China - 1/13/2017
  • "Abicipar Pegol (Anti-Vegf Darpin) Phase 2, Doublemasked, Randomized Study In Treatment-Na�ve Patients With Neovascular Age-Related Macular Degeneration" 
    Bordeaux, France - 1/7/2016
  • Join now to see all

Other

  • Guidelines for Interpreting Retinal Photographs and Coding Findings in the Submacular Surgery trials: SSt report NO. 8. 
    Submacular Surgery Trials Research Group
  • Histo-pathological and Ultrastructural Features of Surgically-excised Subfoveal Choroidal Neovascular Lesions: SST Report NO. 7. 
    Submacular Surgery Trials Research Group

Press Mentions

  • Aviceda Therapeutics Announces Formation of Executive Team
    Aviceda Therapeutics Announces Formation of Executive TeamJanuary 11th, 2021
  • NEW PRODUCT APPLICATIONS: Yutiq Implant for Chronic Noninfectious Posterior-Segment Uveitis
    NEW PRODUCT APPLICATIONS: Yutiq Implant for Chronic Noninfectious Posterior-Segment UveitisApril 1st, 2019

Professional Memberships

Hospital Affiliations